ZA200300216B - 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta. - Google Patents

3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta. Download PDF

Info

Publication number
ZA200300216B
ZA200300216B ZA200300216A ZA200300216A ZA200300216B ZA 200300216 B ZA200300216 B ZA 200300216B ZA 200300216 A ZA200300216 A ZA 200300216A ZA 200300216 A ZA200300216 A ZA 200300216A ZA 200300216 B ZA200300216 B ZA 200300216B
Authority
ZA
South Africa
Prior art keywords
gsk
compound
disease
heteroalkyl
hydrogen
Prior art date
Application number
ZA200300216A
Other languages
English (en)
Inventor
Leyi Gong
Gary Allen Peltz
Andrew Grupe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200300216B publication Critical patent/ZA200300216B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200300216A 2000-07-27 2003-01-08 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta. ZA200300216B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
ZA200300216B true ZA200300216B (en) 2004-04-08

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200300216A ZA200300216B (en) 2000-07-27 2003-01-08 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta.

Country Status (31)

Country Link
US (2) US6479490B2 (cg-RX-API-DMAC7.html)
EP (1) EP1307447B1 (cg-RX-API-DMAC7.html)
JP (1) JP3984157B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030017655A (cg-RX-API-DMAC7.html)
CN (1) CN1185229C (cg-RX-API-DMAC7.html)
AR (1) AR033989A1 (cg-RX-API-DMAC7.html)
AT (1) ATE284885T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001293702A1 (cg-RX-API-DMAC7.html)
BR (1) BR0112965A (cg-RX-API-DMAC7.html)
CA (1) CA2417277A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2003555A3 (cg-RX-API-DMAC7.html)
DE (1) DE60107857T2 (cg-RX-API-DMAC7.html)
EC (1) ECSP034452A (cg-RX-API-DMAC7.html)
ES (1) ES2233691T3 (cg-RX-API-DMAC7.html)
GT (1) GT200100151A (cg-RX-API-DMAC7.html)
HR (1) HRP20030030A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301431A2 (cg-RX-API-DMAC7.html)
IL (1) IL153851A0 (cg-RX-API-DMAC7.html)
JO (1) JO2293B1 (cg-RX-API-DMAC7.html)
MA (1) MA26936A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000695A (cg-RX-API-DMAC7.html)
NO (1) NO20030328L (cg-RX-API-DMAC7.html)
NZ (1) NZ523462A (cg-RX-API-DMAC7.html)
PA (1) PA8523001A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020338A1 (cg-RX-API-DMAC7.html)
PL (1) PL366701A1 (cg-RX-API-DMAC7.html)
RU (1) RU2003104796A (cg-RX-API-DMAC7.html)
UY (1) UY26857A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002010158A2 (cg-RX-API-DMAC7.html)
YU (1) YU4403A (cg-RX-API-DMAC7.html)
ZA (1) ZA200300216B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224932A4 (en) * 1999-08-20 2002-10-16 Sagami Chem Res ACTIVE SUBSTANCES TO INHIBIT CELL DEATH
PL366009A1 (en) * 2000-10-02 2005-01-24 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
DE60140201D1 (en) * 2000-11-07 2009-11-26 Novartis Ag Indolylmaleimidderivative als proteinkinase-c-inhibitoren
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
JP2005532982A (ja) * 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
ES2316756T3 (es) * 2002-01-10 2009-04-16 F. Hoffmann-La Roche Ag Uso de un inhibidor de gsk-3beta en la fabricacion de un medicamento para incrementar la formacion osea.
EP1483265B1 (en) 2002-03-05 2006-11-22 Eli Lilly And Company Purine derivatives as kinase inhibitors
US7405305B2 (en) 2002-03-08 2008-07-29 Eli Lilly And Company Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
CN1671694A (zh) 2002-06-05 2005-09-21 詹森药业有限公司 作为激酶抑制剂的二吲哚基-顺丁烯二酰亚胺衍生物
CA2488798A1 (en) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
EP1682103A1 (en) * 2003-10-27 2006-07-26 Novartis AG Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
CN1949967B (zh) * 2004-05-12 2012-02-01 拜尔作物科学有限公司 植物生长调节作用
CA2589127C (en) 2004-12-08 2013-02-05 Johannes Gutenberg-Universitat Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
JP4747364B2 (ja) 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
CA2729259A1 (en) * 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. 1,2-disubstituted heterocyclic compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2012033225A1 (en) 2010-09-08 2012-03-15 Sumitomo Chemical Company, Limited Method for producing pyridazinone compounds and intermediate thereof
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN112538458B (zh) 2020-11-26 2025-10-31 北京孟眸生物科技有限公司 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
EP0868195A2 (en) 1995-12-20 1998-10-07 Medical Research Council Control of protein synthesis, and screening method for agents
AU2819397A (en) 1996-05-07 1997-11-26 Presidents And Fellows Of Harvard College Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
ES2233691T3 (es) 2005-06-16
CN1444581A (zh) 2003-09-24
NO20030328D0 (no) 2003-01-22
YU4403A (sh) 2006-05-25
UY26857A1 (es) 2002-01-31
GT200100151A (es) 2002-05-23
PA8523001A1 (es) 2002-10-24
NZ523462A (en) 2004-09-24
RU2003104796A (ru) 2004-08-20
BR0112965A (pt) 2003-07-08
PL366701A1 (en) 2005-02-07
KR20030017655A (ko) 2003-03-03
IL153851A0 (en) 2003-07-31
US6479490B2 (en) 2002-11-12
NO20030328L (no) 2003-01-22
AR033989A1 (es) 2004-01-21
WO2002010158A2 (en) 2002-02-07
US20020188018A1 (en) 2002-12-12
DE60107857T2 (de) 2005-12-08
AU2001293702A1 (en) 2002-02-13
JP2004505078A (ja) 2004-02-19
ATE284885T1 (de) 2005-01-15
US20020052397A1 (en) 2002-05-02
HUP0301431A2 (hu) 2003-08-28
JP3984157B2 (ja) 2007-10-03
MA26936A1 (fr) 2004-12-20
DE60107857D1 (de) 2005-01-20
HK1058670A1 (en) 2004-05-28
PE20020338A1 (es) 2002-04-23
EP1307447A2 (en) 2003-05-07
EP1307447B1 (en) 2004-12-15
CN1185229C (zh) 2005-01-19
MXPA03000695A (es) 2003-06-04
JO2293B1 (en) 2005-09-12
CA2417277A1 (en) 2002-02-07
HRP20030030A2 (en) 2005-02-28
WO2002010158A3 (en) 2002-05-16
ECSP034452A (es) 2003-03-10
CZ2003555A3 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
ZA200300216B (en) 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta.
CN105492008B (zh) 用于抑制fasn的化合物及组合物
AP715A (en) Quinoline and quinazoline compounds useful in therapy.
US7625889B2 (en) Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists
CA2670422C (en) Spiroketone acetyl-coa carboxylase inhibitors
EP0464558B1 (en) Antimigraine alkoxypyrimidine derivatives
JP2002536360A (ja) インドール誘導体およびそのmcp−1受容体拮抗剤としての使用
JP2002536362A (ja) 抗炎症剤としてのインドール誘導体
JPH09507066A (ja) プロテインキナーゼc阻害剤
EP1689739B1 (en) Azole-based kinase inhibitors
WO2023086350A1 (en) Alkyne-containing antiviral agents
HU193754B (en) Process for preparing pyrrolo-benzimidazoles
RS63671B1 (sr) Supstitutisani derivati triazolo hinoksalina
KR20070113286A (ko) 아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
HU200337B (en) Process for producing substituted 6-phenyldihydro-3/2h/-pyridazinone derivatives and pharmaceutical compositions comprising such compounds
TW200403233A (en) Chemical compounds
CN102316738A (zh) 作为激酶抑制剂的酰胺类
AU707770B2 (en) Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl- pyridinyl and pyrimidinylpiperazines
ES2427968T3 (es) Nuevos derivados de indol que tienen un grupo carbamoilo, un grupo ureido y un grupo oxi sustituido
KR20020064374A (ko) Mcp-1 수용체 길항제인 인돌 유도체
TW219937B (cg-RX-API-DMAC7.html)
Mokhtari et al. Synthesis of 3-Arylidene and 3-Arylimine Oxindole Derivatives and Evalu-ation of Their Src Kinase Inhibitory and Antiproliferative Activities
HK40048161A (en) Substituted triazolo quinoxaline derivatives
HK40048161B (en) Substituted triazolo quinoxaline derivatives
HK1058670B (en) 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta